KRAS and cancer: Although only a modest overlap was found among these identified candidates (probably due to differences in cell types and experimental setting) and some candidate genes lack effective inhibitors (for example, the TF GATA2), the strategy aimed at synthetic lethality did open up a new avenue to treat KRAS-driven cancers.